What we cover
Biologics & biosimilars
TNF, IL-23, JAK, and the biosimilar wave reshaping the cost base across rheumatology, dermatology, and gastroenterology.
Disease overlap
How autoimmune comorbidities cluster and what that means for sequencing, switching, and combination strategies.
Pipeline
Oral small molecules, novel mechanisms, and what comes after the JAK class.
Access
Step therapy, prior authorisation, and the patient-side cost reality of long-term biologic use.
Latest signals
See all →Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
Snapshots
See all →Systemic sclerosis therapy reference (2026)
Reference snapshot of systemic sclerosis therapy across organ-domain-specific and emerging disease-modifying tiers.
ANCA-associated vasculitis therapy reference (2026)
Reference snapshot of ANCA-associated vasculitis therapy across induction, maintenance, and refractory disease.
Lupus nephritis therapy reference (2026)
Reference snapshot of lupus nephritis therapy across induction and maintenance phases.
Explained
See all →What is systemic sclerosis?
Plain-language primer on systemic sclerosis (scleroderma), why it affects multiple organ systems, and what modern therapy can offer.
What is ANCA-associated vasculitis?
Plain-language primer on ANCA-associated vasculitis, why it can affect multiple organs, and how modern therapy works.
What is lupus nephritis?
Plain-language primer on lupus nephritis, why kidney involvement is a turning point in lupus, and how modern therapy works.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.